Neurobiologist with expertise in animal models of neurological and neuropsychiatric disorders including Parkinson’s disease, epilepsies, addiction, and impulse control disorders.
Earned his doctorate at the University of Bremen and joined Prof. Richter’s group in 2020. Previous postdoctoral associations at FU Berlin, SUNY Buffalo, NY, USA, and TiHo Hannover (Gernert group) addressed pharmacological approaches to treat pharmacoresistent epilepsies and modulate the endocannabinoid influence on reward- and drug-seeking, chemogenetic tools to unravel the implication of mesolimbic GABA projections in motivation and addiction, and telemetric monitoring of neurophysiological parameters, e.g., thermoregulation.
Goal is further disentangle the physiology and pathophysiology of basal ganglia circuits in order to explore new therapeutic drugs for neurological diseases including epilepsies and Parkinson’s disease.
- Effects of brain penetrating drugs on neuronal dysfunction in a mouse model of Parkinson’s disease
- Targeted drug microinfusion into the subthalamic nucleus as a therapeutic strategy for epilepsy
- Animal models for Parkinson’s disease, seizures and epilepsy
- Behavioral pharmacology
- Intracerebral pharmacological interventions
- Behavioral phenotyping of mice and rats
- Immunohistochemical analysis